Next Article in Journal / Special Issue
Enzyme-Linked Immunosorbent Spot Assay for the Detection of Wilms’ Tumor 1-Specific T Cells Induced by Dendritic Cell Vaccination
Previous Article in Journal
Circulating MicroRNAs as Biomarkers and Mediators of Cell–Cell Communication in Cancer
Article Menu

Export Article

Open AccessFeature PaperReview
Biomedicines 2015, 3(4), 282-303; doi:10.3390/biomedicines3040282

Primary Human Blood Dendritic Cells for Cancer Immunotherapy—Tailoring the Immune Response by Dendritic Cell Maturation

1
Department of Tumor Immunology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, GA Nijmegen 6525, The Netherlands
2
Department of Medical Oncology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, GA Nijmegen 6525, The Netherlands
*
Author to whom correspondence should be addressed.
Academic Editor: Vincenzo Cerullo
Received: 10 November 2015 / Revised: 23 November 2015 / Accepted: 25 November 2015 / Published: 2 December 2015
(This article belongs to the Special Issue Dendritic Cells and Cancer Immunotherapy)
View Full-Text   |   Download PDF [1303 KB, uploaded 2 December 2015]   |  

Abstract

Dendritic cell (DC)-based cancer vaccines hold the great promise of tipping the balance from tolerance of the tumor to rejection. In the last two decades, we have gained tremendous knowledge about DC-based cancer vaccines. The maturation of DCs has proven indispensable to induce immunogenic T cell responses. We review the insights gained from the development of maturation cocktails in monocyte derived DC-based trials. More recently, we have also gained insights into the functional specialization of primary human blood DC subsets. In peripheral human blood, we can distinguish at least three primary DC subsets, namely CD1c+ and CD141+ myeloid DCs and plasmacytoid DCs. We reflect the current knowledge on maturation and T helper polarization by these blood DC subsets in the context of DC-based cancer vaccines. The maturation stimulus in combination with the DC subset will determine the type of T cell response that is induced. First trials with these natural DCs underline their excellent in vivo functioning and mark them as promising tools for future vaccination strategies. View Full-Text
Keywords: human blood DC (dendritic cell) subsets; maturation; DC-based cancer vaccines; plasmacytoid DC; myeloid DC; CD141+ myeloid DC (mDC); CD1c+ mDC human blood DC (dendritic cell) subsets; maturation; DC-based cancer vaccines; plasmacytoid DC; myeloid DC; CD141+ myeloid DC (mDC); CD1c+ mDC
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Sittig, S.P.; de Vries, I.J.M.; Schreibelt, G. Primary Human Blood Dendritic Cells for Cancer Immunotherapy—Tailoring the Immune Response by Dendritic Cell Maturation. Biomedicines 2015, 3, 282-303.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top